SRR12475139
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR12475121 | — | — | 0.927 |
| 2 | SRR17866835 | — | — | 0.922 |
| 3 | 0429cf04-6e5c-41dd-b4a9-4f7ad15d15bc | — | — | 0.884 |
| 4 | SRR12475112 | — | — | 0.878 |
| 5 | SRR12475115 | — | — | 0.860 |
| 6 | SRR12475148 | — | — | 0.847 |
| 7 | TCGA-55-7284-01B-11R-2241-07 | — | cohortA1 | 0.846 |
| 8 | TCGA-97-7552-01A-11R-2039-07 | — | cohortA1 | 0.846 |
| 9 | SRR17866825 | — | — | 0.844 |
| 10 | TCGA-91-7771-01A-11R-2170-07 | — | cohortA2 | 0.841 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.430 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.370 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.330 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.320 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.300 | Temsirolimus | — uncovered |
| COMPLEMENT | 0.280 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.280 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.260 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.250 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.250 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.220 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.210 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.160 | Cobimetinib | — uncovered |
| HYPOXIA | 0.150 | Idelalisib | — uncovered |
| APOPTOSIS | 0.100 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.100 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.100 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.080 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.080 | Inavolisib | — uncovered |
| MYOGENESIS | 0.080 | Inavolisib | — uncovered |